IOVA

Iovance Biotherapeutics, Inc. - Common Stock (IOVA)

About Iovance Biotherapeutics, Inc. - Common Stock (IOVA)

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Details

Daily high

$10.64

Daily low

$10.03

Price at open

$10.43

52 Week High

$10.98

52 Week Low

$1.76

Market cap

4.6B

Dividend yield

Volume

13.1M

Avg. volume

13.2M

P/E ratio

-14.21

Iovance Biotherapeutics, Inc. - Common Stock News